IOVA — Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Q4 Revenue: Approximately $87 million, reflecting a 30% increase from the previous quarter.
• Full Year Revenue: Total revenue of about $264 million, up 61% year-over-year, driven by a 112% increase in Amtagvi sales.
• Gross Margin: Achieved a 50% gross margin in Q4, up from 43% in Q3, attributed to operational efficiencies and internalized manufacturing.
• Cash Position: Ended the year with approximately $303 million, extending the cash runway into Q3 2027.

2. Strategic Updates and Business Highlights:

• Amtagvi Adoption: Strong commercial uptake in advanced melanoma, with expectations of reaching over $1 billion in peak U.S. sales.
• TIL Pipeline Expansion: Fast-track designation received from the FDA for lifileucel in non-small cell lung cancer (NSCLC), with plans for a supplemental biologics license application (BLA) by H2 2027.
• New Indications: Positive early data for lifileucel in advanced soft tissue sarcomas, showing a 50% confirmed response rate, leading to plans for a registrational trial.
• Operational Excellence: Focus on improving manufacturing processes and efficiencies, with all manufacturing now centralized at the Iovance Cell-Therapy Center (ICTC).

3. Forward Guidance and Outlook:

• 2026 Revenue Projections: Specific guidance to be provided soon, with expectations of remarkable growth driven by Amtagvi and new indications.
• Market Potential: Anticipated significant revenue contributions from both melanoma and the expanding NSCLC market, with a potential combined market opportunity exceeding $10 billion.

4. Bad News, Challenges, or Points of Concern:

• Market Penetration: While there is positive momentum, the company needs to ensure sustained demand and effective penetration into community treatment centers.
• Regulatory Risks: The timeline for approvals and the success of ongoing clinical trials remain uncertain, which could impact future revenue projections.
• Competitive Landscape: The company faces competition in the immunotherapy space, particularly as it expands into new indications.

5. Notable Q&A Insights:

• Enrollment Trends: Enrollment in the TILVANCE-301 trial is accelerating, but the timeline for first-line melanoma data remains uncertain.
• Proleukin Revenue: The uptick in Proleukin sales in Q4 was driven primarily by Amtagvi demand, with expectations for stabilization moving forward.
• Community ATC Growth: The company anticipates a gradual increase in the number of community ATCs, similar to the academic centers' initial ramp-up.
• Real-World Data Impact: Recent real-world data presented at a conference is expected to enhance physician engagement and treatment uptake.

Overall, Iovance Biotherapeutics demonstrated strong financial growth and strategic advancements in 2025, positioning itself well for future opportunities, though it must navigate regulatory and competitive challenges ahead.